Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand

Blood

Volumn 92, Issue 8, 1998, Pages 2830-2843

  Baker, Matthew P ^b   Eliopoulos, Aristides G ^b   Young, Lawrence S ^b   Armitage, Richard J ^b   Gregory, Christopher D ^b   Gordon, John ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL SURFACE; CORRELATION FUNCTION; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT;

EID: 0032532633     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.8.2830     Document Type: Article

References (34)

1. Geser A, Lenoir GM, Anvret M, Bornkamm G, Klein G, Williams EH, Wright DH, De The G: Epstein-Barr virus markers in a series of Burkiit's lymphomas from the West Nile district of Uganda. Eur J Cancer Clin Oncol 19:1393, 1983
2. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, Rickinson AB: Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349:612, 1991
3. Gregory CD, Rowe M, Rickinson AB: Different Epstein-Barr virus B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71:1481, 1990
4. Gregory CD, Milner AE: Regulation of cell survival in Burkitt lymphoma: Implications from studies of apoptosis following cold-shock treatment. Int J Cancer 57:419, 1994
5. Holder MJ, Wang H, Milner AE, Casamjor M, Armitage R, Spriggs MK, Fanslow, WC, MacLennan ICM, Gregory CD, Gordon J: Suppresssion of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur J Immunol 23:2368, 1993
6. Van Kooten C, Banchereau J: CD40-CD40 ligand: A multifunctional receptor-ligand pair. Adv Immunol 61:1, 1992
7. Braesch-Andersen S, Paulie S, Koho H, Nika H, Aspenstrom P, Perlmann P: Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen Cdw40. J Immunol 142:562, 1989
8. MacDonald I, Wang H, Grand R, Armitage RJ, Fanslow WC, Gregory CD, Gordon J: Transforming growth factor-β1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. Blood 87:1147, 1996
9. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfat I, Armitage RJ, Fanslow WC, Spriggs MK, Murphy WJ: Inhibition of human B cell lymphoma growth by CD40 stimulation. Blood 83:2787, 1994
10. Holder MJ, Liu Y-J, Defrance T, Flores-Romo L, MacLennan ICM, Gordon J: Growth factor requirements for the stimulation of germinal center cells: Evidence of an IL-2-dependent pathway of development. Int Immunol 3:1243, 1991
11. de Vries JE, Gauchat J-F, Aversa GG, Punnonen J, Gascan H, Yssel H: Regulation of IgE synthesis by cytokines. Curr Opin Immunol 3:851, 1991
12. Zhang K, Clark EA, Saxon A: CD40 stimulation provides an IFN-gamma-independent and IL-4-dependent differentiation directly to human B cells for IgE production. J Immunol 146:1836, 1991
13. Gordon J, Millsum MJ, Guy GR, Ledbetter JA: Resting B lymphocytes can be triggered directly through the Cdw40 (Bp50) antigen. A comparison with IL4-mediated signaling. J Immunol 140: 1425, 1988
14. Rowe M, Rooney CM, Rickinson AB, Lenoir GM, Rupant H, Moss DJ, Stein H, Epstein MA: Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer 35:435, 1985
15. Rowe M, Rooney CM, Rickinson AB, Lenoir GM, Rickinson AB: Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer 37:363, 1986
16. Rowe M, Rowe DT, Gregory CD, Young LS, Farrel PJ, Rupani H, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6:2743, 1987
17. Rooney CM, Gregory CD, Rowe M, Finerty S, Edwards C, Rupani H, Rickinson AB: Endemic Burkitt's lymphoma: Phenotypic analysis of tumour biopsy cells and of derived tumor cell lines. J Natl Cancer Inst 77:681, 1986
18. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJO, Reed J, Kieff E, Young LS: CD40-induced growth inhibition is mimicked by Epstein-Barr virus-encoded LMP1-involvement of TRAF3 as a comediator. Oncogene 13:2243, 1996
19. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251, 1980
20. Cheng G, Baltimore D: TANK, a co-inducer with TRAF2 of TNF-and CD40L-mediated NF-κB activation. Genes Dev 10:963, 1996
21. Gordon J: CD40 and its ligand: Central players in B lymphocyte survival, growth, and differentiation. Blood Rev 9:53, 1995
22. Milner AE, Johnson GD, Gregory CD: Prevention of programmed cell death in Burkitt lymphoma cell lines by bcl-2-dependent and -independent mechanisms. Int J Cancer 52:636, 1992
23. L in CD40-mediated rescue from anti-μ-induced apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 25:1352, 1995
24. Bargou RC, Bommert K, Weinmann P, Daniel PT, Wagener C, Mapara MY, Dorken B: Induction of Bax-α precedes apoptosis in a human B lymphoma cell line: Potential role of the bcl-2 gene family in surface IgM-mediated apoptosis. Eur J Immunol 25:770, 1995
25. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597, 1993
26. Oltiva ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerises in vivo with a conserved homolog, Bax, that accelerates progarmmed cell death. Cell, 74:609, 1993
27. Wang H, Grand RJA, Milner AE, Armitage RJ, Gordon J, Gregory CD: Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: Relationship to the cell-cycle and role of the retinoblastoma protein. Oncogene 13:373, 1996
28. Gregory CD, Edwards CD, Milner A, Weils J, Lipinski M, Rowe M, Tursz T, Rickinson AB: Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int J Cancer 42:213, 1988
29. Arpin C, Dechanet J, Van Kooten C, Merville P, Grouard G, Briere F, Banchereau J, Liu Y-J: Generation of memory B cells and plasma cells in vitro. Science 268:720, 1995
30. Favrot MC, Maritaz O, Suzuki T, Cooper M, Philip I, Philip T, Lenoir G: EBV-negative and positive Burkitt cell lines variably express receptors for B-cell activation and differentiation, Int J Cancer 38:901, 1986
31. Calender A, Cordier M, Billaud M, Lenoir GM: Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int J Cancer 46:658, 1990
32. Silins SL, Sculley TB: Modulation of vimentin, the CD40 activation antigen and Burkitt's lymphoma antigen (CD77) by the Epstein-Barr virus nuclear antigen EBNA-4. Virology 202:16, 1995
33. Murphy WJ, Funakoshi S, Beckwith M, Rushing SE, Conley DK, Armitage RJ, Fanslow WC, Roger HC, Taub DD, Ruscetti FW, Longo DL: Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in SCID mice given human peripheral blood lymphocytes. Blood 86:1946, 1995
34. Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, Holden W, Brenner M: CD40 ligand induces an anti-leukemia immune response in vivo, Rlood 90:1927, 1997